Core Insights - The article discusses three mid-cap stocks with potential for significant growth, specifically CRISPR Therapeutics, Viking Therapeutics, and e.l.f. Beauty, which have market caps between $2 billion and $10 billion [1][2]. CRISPR Therapeutics - CRISPR Therapeutics has a market cap of approximately $5.2 billion and offers an approved gene therapy treatment, Casgevy, for sickle cell disease and transfusion-dependent beta thalassemia, valued at over $2 million per treatment [3][5]. - The rollout of Casgevy has been slow, with around 300 patients referred to treatment centers, leading to investor disappointment; the company has reported net losses of $451 million over the past nine months [5][6]. Viking Therapeutics - Viking Therapeutics, with a market cap of around $4.3 billion, is developing a GLP-1 weight loss drug, VK2735, which is currently in phase 3 trials [7][8]. - In earlier trials, VK2735 helped participants lose up to 14.7% of their body weight in 13 weeks; the potential market for GLP-1 drugs could reach $95 billion by 2030 [10][11]. - Viking has incurred losses exceeding $237 million over the past year and does not currently generate revenue, making it a higher-risk investment [11]. e.l.f. Beauty - e.l.f. Beauty has a market cap of approximately $4 billion and is popular among teens, ranking as the top cosmetics brand with a 36% mindshare in a recent survey [12]. - The company projects revenue of around $1.6 billion and adjusted net income of at least $165 million for the year, despite share prices dropping over 40% due to tariff exposure from manufacturing 80% of its products in China [13][14]. - e.l.f. has raised prices on many products by $1, which may help it navigate current challenges; if tariffs are resolved, the stock could see significant growth [14].